RA patients who were about to commence treatment with methotrexate (MTX) were selected from the Rheumatoid Arthritis Medication Study. Using European League Against Rheumatism (EULAR) response criteria, 42 patients were categorized as good responders and 43 as nonresponders at 6 months following the initiation of MTX treatment. Data on whole blood transcript expression were generatedData on whole blood transcript expression were generated, and supervised machine learning methods were used to predict a EULAR nonresponse. See manuscript for pre-processing / QC steps applied to these data (PubMed-ID: 30615300).
|Date made available||21 Apr 2020|